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Abstract 
Objective: It would be beneficial  to find genetic predictors of antidepressant response to 
help personalise treatment of major depressive disorder (MDD). Rare  copy number variants 
(CNVs) have been implicated in several psychiatric disorders including MDD, but their role 
in antidepressant response is yet to be investigated.  
Methods: CNVs were assessed using genome wide microarrays in 1565 individuals from the 
NEWMEDS consortium where we had prospective data on outcome of treatment of MDD 
with either a serotonergic or noradrenergic antidepressant for up to 12 weeks.  
Results: We found no association between presence of rare CNVs, number of CNVs or CNV 
‘burden’ and antidepressant response, response to serotonergic antidepressants, response to 
noradrenergic antidepressant or differential response to serotonergic versus noradrenergic 
antidepressants. Neither was there a relationship between antidepressant response and  
common CNVs.  
Conclusions: Together with similarly negative data for common genetic variants, our present  
findings imply that personalising treatment with antidepressants based on genetic information 
will be a more complex task than had hitherto been expected. 
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Introduction: 
Antidepressants are the first line of treatment for major depressive disorder (MDD). However 
individuals vary widely in their response to treatment and currently there is no way to predict 
an individual’s response. Prediction of how an individual will respond to a specific treatment 
is needed to reduce the delay to alleviation of symptoms and the cost of treatment and 
disability. While the existence of any single common genetic variant with a large enough 
effect to meaningfully predict antidepressant response is unlikely (1-5) we have shown that 
antidepressant response is moderately heritable (Tansey et at BP paper) and other forms of 
genetic variation remain to be investigated for a role in antidepressant response.  
Copy number variants (CNVs) are submicroscopic deletions and duplications in genomic 
DNA that have been implicated in a variety of different psychiatric disorders including 
schizophrenia, autism, ADHD and MDD (6-12). Individuals with MDD have been shown to 
have an increased burden of rare deleterious CNVs compared to controls (12). We 
hypothesise that rare deleterious CNVs may also affect how individuals respond to treatment 
with antidepressants. To date, there is no published report on the relationship between CNVs 
and response to treatment with antidepressants. In this manuscript, we use information from 
Illumina genotyping arrays to assess the role of CNVs in response to treatment with 
antidepressants in individuals with MDD.  
Materials and Methods: 
Sample 
The Novel Methods leading to New Medications in Depression and Schizophrenia 
(NEWMEDS)(http://www.newmeds-europe.com) sample included 2,146 treatment seeking 
adults diagnosed with MDD according to DSM-IV/ICD-10, with prospective data on 
outcome of treatment with SRI or NRI antidepressants for up to 12 weeks (1). This sample 
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combined data from studies conducted by academic institutions (GENDEP, n=868; 
GENPOD, n=601; GODS, n=131) (2, 13, 14) and pharmaceutical industry members of the 
European Federation of Pharmaceutical Industries and Associations (EFPIA; Pfizer, n=355; 
GSK, n=191). Individuals were excluded if they had diagnoses of schizophrenia, 
schizoaffective disorder, bipolar disorder or current alcohol or drug dependence. Individuals 
were given either an antidepressant that acts primarily through blocking the reuptake of 
serotonin (SSRI: escitalopram, citalopram, paroxetine, sertraline, fluoxetine) or an 
antidepressant that acts primarily through blocking the reuptake of norepinephrine (NRI: 
nortriptyline, reboxetine).  
Further information on the component studies can be found in Supplementary materials.  
Genotyping 
All DNA samples were from venous blood. Information was available from 1,166 samples 
genotyped on the Illumina 660W BeadChip and 746 samples genotyped on the Illumina 
610Quad BeadChip (Illumina, San Diego, USA), which have identical tag SNP coverage. 
Raw Illumina data in the form of .idat files were imported into GenomeStudio and processed 
according to Illumina's recommended guidelines to derive the log R ratio (LRR) and B allele 
frequency (BAF) for each marker within each sample. A consensus marker set between the 
Ilumina arrays of 561,733 markers was used.  
CNV Calling 
LRR and BAF data was processed with PennCNV (15) (version dated June 2011) and 
QuantiSNP (16) (version 2.3) using all markers and within-sample correction for waviness 
artefacts attributable to local GC content. The 'HD' prior parameter settings for LRR 
thresholds were used within the QuantiSNP analysis, as recommended by the author.  
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Due to variability between calling algorithms, we used two CNV calling algorithms 
(PennCNV and QuantiSNP) to minimize the number of false calls. A recent study showed the 
use of multiple calling algorithms increases the likelihood of validation by PCR to greater 
than 95% (17). CNV calls were merged between PennCNV and QuantiSNP. Specifically, a 
call or calls made by QuantiSNP or PennCNV were merged into a consensus call if, within 
the same sample, the calls overlapped. Only calls with overlap of greater than 50% between 
the two regions were used for onward analysis. We excluded any call made with less than 10 
consecutive markers, and any CNV where 50% of the call covered a region within 500kb of 
the telomere, centromere or immunoglobulin regions, or a region where the marker density of 
the consensus marker set dropped below one marker in 200,000bp. 
Sample and CNV Quality Control 
Sample QC was performed using sample-wide metrics calculated by PennCNV. A sample 
was excluded from further analysis if any of the following criteria were met: (A) the standard 
deviation of the LRR for autosomes was greater than 0.25, (B) the standard deviation for the 
BAF for autosomes was greater than 0.04, (C) the drift of BAF values exceeded 0.002, (D) 
the waviness factor was greater than 0.04 or less than -0.04, (E) the genotype call rate was 
less than 98%, (F) the logarithm of the total number of CNVs called by either algorithm 
before CNV call QC and after samples were excluded by steps A-E exceeded three standard 
deviations from the mean. 
Only samples which passed quality control for our whole genome association study were 
considered for the analysis of CNVs. This ensured that individuals with ambiguous sex 
(n=22), abnormal heterozygosity (n=16), cryptic relatedness up to third-degree relatives by 
identity by descent (n=20), and non-European ethnicity admixture detected as outliers in an 
iterative EIGENSTRAT analysis of an LD-pruned dataset (n=35) (1) did not impact on the 
association results.  
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Definition of Antidepressant Response Phenotype 
We defined antidepressant response as a proportional reduction in symptoms over the course 
of treatment, consistent with previous reports (1, 2). Proportional improvement in depression 
severity was created for each component study based on the primary depression rating scale 
from baseline to the end of treatment, adjusted for age, sex and recruiting centre. Depression 
severity was measured by one of three primary rating scales (Montgomery-Åsberg 
Depression Rating Scale, Hamilton Rating Scale for Depression, Beck Depression Inventory) 
(18). The adjusted change score for each component study was z-transformed within each 
study to remove correlation between data origin and outcome and to eliminate study specific 
effects. 
Statistical Analysis 
Statistical analyses were done using PLINK (19) and STATA/SE 10 (20). PLINK was used 
to determine number of CNVs and total size of CNVs for each individual. In addition to 
analyzing the effect of all CNVs, we also separately examined the effects of common CNVs 
(found in more than 10% of individuals) and rare CNVs (found in less than 10% of 
individuals). Analyses were undertaken to investigate the effects of harbouring any CNVs, 
and more specifically for the effect of deletion or duplication CNVs. CNVs were further 
annotated as to whether they covering gene-coding regions (genic) or exon-coding regions 
(exonic) as defined by RefSeq gene annotation coordinates obtainable from the UCSC 
genome browser (http://genome.ucsc.edu). For information about the number of individuals 
with a CNV in each of the categories examined, see supplementary materials.  
CNV data were analysed using four linear regressions: (1) the entire sample, (2) only those 
individuals taking a SSRI, (3) only those individuals taking a NRI, (4) differential response to 
treatment with either a SSRI or NRI (CNV by drug interaction). Analyses were co-varied for 
the standard deviation of the log relative ratio and four principal components from the final 
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iteration of the EIGENSTRAT analysis of LD-pruned genetic data to minimise the influence 
of population stratification (1). 
Analyses were also performed within each contributing sample and meta-analysed (see 
Supplementary materials).  
Power Analysis 
We aimed to determine if presence, number or burden of CNVs would predict response to 
antidepressant treatment in a clinically significant way. Simulations based on large 
antidepressant treatment trials have shown that a prediction is usually judged to be clinically 
significant if it explains at least 6.33% of the variance in the response outcome (21). Using 
the pwr package (Power analysis functions along the lines of Cohen (22)) in R (23), we 
calculated the power of our four analyses (whole sample, serotonergic, noradrenergic, and 
gene by drug interaction). All of our analyses had power (greater than 90%) to detect a 
clinically significant finding at the alpha level of p<0.05. All analyses had an adequate 
statistical power (>80%) to detect even a signal that explains only half of what would be 
clinically significant prediction. 
Results 
In the combined sample, 1,565 individuals passed quality control for both the whole genome 
association study and the CNV calls.  
We found no association between presence of any CNV, total number of CNVs or global 
CNV burden and response to any antidepressant, serotonergic antidepressants, noradrenergic 
antidepressants or differential response to serotonergic and noradrenergic antidepressants 
(Table 1). There was no relationship with rare or common CNVs or deletions or duplications.   
We carried out additional analyses, restricted to CNVs which encompassed gene coding 
regions (genic) or exon coding regions (exonic), but we found no significant association 
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between presence of CNV, global number of CNVs or global CNV burden and antidepressant 
response, response to serotonergic antidepressants, response to noradrenergic antidepressants 
or differential response to serotonergic and noradrenergic antidepressants (Tables 2 and 3). 
Furthermore, there was no association with genic or exonic rare or common CNVs or 
deletions or duplications. 
Discussion 
CNVs have been implicated in the aetiology of several psychiatric disorders including major 
depression where we have previously reported an overall excess of deletions affecting exons 
in cases compared with controls (Rucker paper). It is reasonable to hypothesise that CNVs 
might also influence the form or course of the illness and this is the first investigation into the 
relationship between antidepressant response and CNVs. We took a comprehensive approach 
to explore the role of CNVs in response to antidepressant treatment by assessing both global 
number and burden of CNVs and considering possibly specific roles of duplications, 
deletions, rare, common, genic and exonic CNVs. However in each of these analyses, we 
found no association between CNVs and antidepressant response.  
Our negative results for the role of CNVs and antidepressant response add to the growing 
literature of negative genome wide association studies (GWAS) for antidepressant response 
(1-5). By contrast, analysis of GWAS data on response to antidepressants provides perhaps 
the best evidence to date that it is a heritable trait (Tansey in press BP paper). While there are 
still other forms of genetic variation that have yet to be investigated, such as rare or personal 
single nucleotide mutations, it seems unlikely that  any single genetic variation or simple 
combination of variants will be clinically useful in the personalising antidepressant 
medication. What is emerging instead is that antidepressant response is a complex polygenic 
(and likely polyenvironmental) quantitative trait. It remains to be seen whether more complex 
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combinatorial approaches, based for example on machine learning, can help tease out key 
genetic elements.  
Our study has several limitations which should be taken into consideration when interpreting 
these results. Our analysis classifies antidepressants into mechanism of action (serotonergic 
versus noradrenergic) and cannot inform about the role of CNVs for a specific drug. 
Furthermore, our analysis focused on global measures of CNVs rather than specific deletions 
or duplication events which may affect an individual’s response to treatment. We obtained 
our large sample by bringing together numerous different studies which differ by rating scale 
used and method to recruit subjects. We took these steps as we are interested in predictors of 
antidepressant response which generalize to most individuals with MDD. Furthermore, our 
studies focus only on individuals of Caucasian/European ancestry and monoaminergic 
antidepressants. Results in other population and/or in drugs whose mechanism of action is 
non-monoaminergic may yield different results.  
Conclusions 
We have investigated for the first time the role of CNVs in response to treatment with 
antidepressants. We find no association between antidepressant response for global number 
or burden of CNVs. The growing literature of negative genetic associations for antidepressant 
response implies that use of some types of genetic information to personalise treatment of 
MDD is not likely in the near future. Future large studies investigating known functional 
variants not adequately captured by this type of analysis and various clinical and biological 
features, such as transcriptomics and/or epigenomics, are needed along with complex 
multivariate prediction algorithms to personalise treatment of MDD with antidepressants.  
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Table 1: NEWMEDS CNV results for ALL CNVs. Regression coefficient is standardized and can be interpreted as a measure of effect size.. Positive values of regression coefficient mean 
that carriers of more minor alleles had better treatment outcome. Negative values of regression coefficient mean that carriers of more minor alleles had worse outcomes. 
All CNVs Whole Sample Analysis 
(n=1,565) 
Serotonergic Analysis 
(n=1,046) 
Noradrenergic Analysis 
(n=519) 
Gene by Drug Interaction 
(n=1,565) 
Coefficient 
(SE) 
p-value Coefficient 
(SE) 
p-value Coefficient 
(SE) 
p-value Coefficient 
(SE) 
p-value 
Any CNV -0.015 
(0.058) 
0.799 
-0.0001 
(0.071) 
0.999 
-0.034 
(0.104) 
0.742 
-0.022 
(0.126) 
0.863 
Number of CNVs  -0.012 
(0.021) 
0.572 
-0.022 
(0.025) 
0.384 
0.022 
(0.037) 
0.557 
0.045 
(0.045) 
0.315 
Burden of CNVs  0.00002 
(0.00005) 
0.739 
-0.00002 
(0.00007) 
0.786 
0.00005 
(0.00006) 
0.400 
0.00008 
(0.0001) 
0.382 
Any deletion CNV -0.082 
(0.051) 
0.108 
-0.108 
(0.062) 
0.085 
-0.013 
(0.090) 
0.884 
0.100 
(0.109) 
0.358 
Number of deletion CNVs  -0.043 
(0.036) 
0.232 
-0.045 
(0.044) 
0.299 
-0.025 
(0.062) 
0.686 
0.022 
(0.076) 
0.774 
Burden of deletion CNVs  0.000009 
(0.00007) 
0.889 
-0.0002 
(0.0001) 
0.286 
0.00006 
(0.00008) 
0.425 
0.0002 
(0.0002) 
0.161 
Any duplication CNV 0.038 
(0.051) 
0.461 
0.041 
(0.062) 
0.514 
0.044 
(0.090) 
0.623 
0.013 
(0.109) 
0.908 
Number of duplication CNVs  0.004 
(0.025) 
0.870 
-0.010 
(0.031) 
0.739 
0.042 
(0.043) 
0.329 
0.054 
(0.054) 
0.313 
Burden of duplication CNVs  0.00002 
(0.00008) 
0.743 
0.00002 
(0.00008) 
0.766 
0.00004 
(0.0001) 
0.759 
0.00002 
(0.0001) 
0.890 
Any rare CNV -0.012 
(0.050) 
0.812 
-0.043 
(0.061) 
0.482 
0.064 
(0.087) 
0.463 
0.119 
(0.106) 
0.263 
Number of rare CNVs  -0.008 
(0.028) 
0.789 
-0.034 
(0.035) 
0.333 
0.058 
(0.049) 
0.241 
0.096 
(0.060) 
0.110 
Burden of rare CNVs  0.00003 
(0.00005) 
0.577 
-0.00001 
(0.00008) 
0.856 
0.00007 
(0.00007) 
0.318 
0.00009 
(0.0001) 
0.367 
Any rare deletion CNV -0.069 
(0.055) 
0.209 
-0.103 
(0.067) 
0.124 
0.016 
(0.096) 
0.870 
0.121 
(0.116) 
0.297 
Number of rare deletion CNVs  -0.033 
(0.042) 
0.436 
-0.047 
(0.052) 
0.365 
0.007 
(0.071) 
0.925 
0.053 
(0.879) 
0.548 
Burden of rare deletion CNVs  0.00002 
(0.00007) 
0.742 
-0.0001 
(0.0002) 
0.363 
0.00007 
(0.00008) 
0.382 
0.0002 
(0.0002) 
0.207 
Any rare duplication CNV 0.020 0.707 -0.021 0.741 0.114 0.207 0.152 0.166 
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(0.052) (0.064) (0.090) (0.110) 
Number of rare duplication CNVs  0.015 
(0.036) 
0.664 
-0.017 
(0.043) 
0.699 
0.091 
(0.062) 
0.140 
0.115 
(0.076) 
0.128 
Burden of rare duplication CNVs  0.00003 
(0.00007) 
0.663 
0.00003 
(0.00009) 
0.744 
0.00005 
(0.0001) 
0.686 
0.00004 
(0.0002) 
0.823 
Any common CNV -0.003 
(0.050) 
0.950 
0.031 
(0.061) 
0.610 
-0.069 
(0.087) 
0.429 
-0.088 
(0.106) 
0.405 
Number of common CNVs  -0.011 
(0.032) 
0.721 
-0.004 
(0.039) 
0.927 
-0.016 
(0.053) 
0.771 
-0.016 
(0.066) 
0.808 
Burden of common CNVs  -0.00008 
(0.0002) 
0.607 
-0.00004 
(0.0002) 
0.824 
-0.0001 
(0.0003) 
0.707 
-0.00007 
(0.0003) 
0.839 
Any common deletion CNV -0.048 
(0.072) 
0.505 
-0.005 
(0.087) 
0.950 
-0.136 
(0.128) 
0.289 
-0.124 
(0.156) 
0.428 
Number of common deletion CNVs  -0.035 
(0.064) 
0.583 
-0.013 
(0.078) 
0.870 
-0.075 
(0.116) 
0.518 
-0.059 
(0.140) 
0.671 
Burden of common deletion CNVs  -0.0002 
(0.0003) 
0.529 
-0.0002 
(0.0004) 
0.657 
-0.0002 
(0.0005) 
0.770 
0.00004 
(0.0006) 
0.955 
Any common duplication CNV 0.013 
(0.051) 
0.799 
0.025 
(0.062) 
0.694 
-0.006 
(0.088) 
0.941 
-0.025 
(0.108) 
0.820 
Number of common duplication CNVs  -0.008 
(0.038) 
0.840 
-0.003 
(0.048) 
0.952 
-0.005 
(0.062) 
0.938 
-0.007 
(0.079) 
0.929 
Burden of common duplication CNVs  -0.00004 
(0.0002) 
0.833 
0.000002 
(0.0003) 
0.995 
-0.00007 
(0.0003) 
0.842 
-0.00008 
(0.0004) 
0.844 
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Table 2: NEWMEDS CNV results for CNVs encompassing regions annotated to harbour genes. Regression coefficient is standardized and can be interpreted as a measure of effect size.. 
Positive values of regression coefficient mean that carriers of more minor alleles had better treatment outcome. Negative values of regression coefficient mean that carriers of more minor alleles 
had worse outcomes. 
GENIC CNVs Whole Sample Analysis 
(n=1,565) 
Serotonergic Analysis 
(n=1,046) 
Noradrenergic Analysis 
(n=519) 
Gene by Drug Interaction 
(n=1,565) 
Coefficient 
(SE) 
p-value Coefficient 
(SE) 
p-value Coefficient 
(SE) 
p-value Coefficient 
(SE) 
p-value 
Any CNV -0.042 
(0.051) 
0.415 
-0.049 
(0.063) 
0.433 
-0.012 
(0.091) 
0.895 
0.049 
(0.110) 
0.658 
Number of CNVs  -0.008 
(0.025) 
0.750 
-0.016 
(0.030) 
0.606 
0.018 
(0.043) 
0.674 
0.041 
(0.052) 
0.438 
Burden of CNVs  0.00003 
(0.00005) 
0.617 
0.00001 
(0.00009) 
0.898 
0.00004 
(0.00007) 
0.519 
0.00005 
(0.0001) 
0.652 
Any deletion CNV -0.082 
(0.060) 
0.172 
-0.068 
(0.073) 
0.354 
-0.098 
(0.105) 
0.350 
-0.002 
(0.128) 
0.986 
Number of deletion CNVs  -0.085 
(0.048) 
0.080 
-0.066 
(0.060) 
0.275 
-0.108 
(0.082) 
0.188 
-0.023 
(0.102) 
0.821 
Burden of deletion CNVs  0.0000005 
(0.00007) 
0.994 
-0.0001 
(0.0002) 
0.382 
0.00004 
(0.00008) 
0.648 
0.0002 
(0.0002) 
0.272 
Any duplication CNV 0.019 
(0.050) 
0.701 
-0.008 
(0.061) 
0.893 
0.091 
(0.087) 
0.298 
0.101 
(0.106) 
0.339 
Number of duplication CNVs  0.019 
(0.029) 
0.506 
0.001 
(0.035) 
0.972 
0.064 
(0.050) 
0.197 
0.065 
(0.061) 
0.284 
Burden of duplication CNVs  0.00005 
(0.00007) 
0.482 
0.00005 
(0.00009) 
0.545 
0.00006 
(0.0001) 
0.624 
0.00002 
(0.0002) 
0.898 
Any rare CNV 0.006 
(0.052) 
0.905 
0.001 
(0.063) 
0.985 
0.031 
(0.089) 
0.729 
0.044 
(0.109) 
0.689 
Number of rare CNVs  0.005 
(0.034) 
0.877 
-0.009 
(0.043) 
0.834 
0.044 
(0.058) 
0.440 
0.067 
(0.072) 
0.350 
Burden of rare CNVs  0.00004 
(0.00005) 
0.446 
0.00003 
(0.00009) 
0.717 
0.00005 
(0.00007) 
0.452 
0.00004 
(0.0001) 
0.748 
Any rare deletion CNV -0.057 
(0.067) 
0.390 
-0.033 
(0.081) 
0.681 
-0.105 
(0.117) 
0.371 
-0.044 
(0.143) 
0.760 
Number of rare deletion CNVs  -0.068 
(0.055) 
0.217 
-0.040 
(0.069) 
0.557 
-0.112 
(0.091) 
0.222 
-0.051 
(0.115) 
0.658 
Burden of rare deletion CNVs  0.00001 
(0.00007) 
0.0858 
-0.0001 
(0.0002) 
0.572 
0.00004 
(0.00008) 
0.649 
0.0002 
(0.0002) 
0.434 
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Any rare duplication CNV 0.038 
(0.055) 
0.490 
-0.011 
(0.068) 
0.866 
0.153 
(0.093) 
0.103 
0.177 
(0.115) 
0.126 
Number of rare duplication CNVs  0.042 
(0.041) 
0.301 
0.009 
(0.050) 
0.861 
0.123 
(0.071) 
0.081 
0.122 
(0.087) 
0.161 
Burden of rare duplication CNVs  0.00006 
(0.00008) 
0.411 
0.00007 
(0.0001) 
0.489 
0.00008 
(0.001) 
0.577 
0.00002 
(0.0002) 
0.895 
Any common CNV -0.026 
(0.050) 
0.601 
-0.041 
(0.062) 
0.502 
0.009 
(0.088) 
0.915 
0.062 
(0.107) 
0.563 
Number of common CNVs  -0.025 
(0.038) 
0.510 
-0.028 
(0.048) 
0.562 
-0.013 
(0.063) 
0.831 
0.014 
(0.079) 
0.859 
Burden of common CNVs  -0.0001 
(0.0002) 
0.476 
-0.0001 
(0.0002) 
0.582 
-0.00009 
(0.0003) 
0.750 
0.00003 
(0.0004) 
0.928 
Any common deletion CNV -0.139 
(0.103) 
0.177 
-0.149 
(0.128) 
0.244 
-0.083 
(0.173) 
0.631 
0.079 
(0.215) 
0.712 
Number of common deletion CNVs  -0.135 
(0.100) 
0.175 
-0.143 
(0.122) 
0.242 
-0.083 
(0173) 
0.631 
0.072 
(0.211) 
0.734 
Burden of common deletion CNVs  -0.0003 
(0.0004) 
0.365 
-0.0005 
(0.0005) 
0.326 
0.00003 
(0.0006) 
0.966 
0.0005 
(0.0008) 
0.500 
Any common duplication CNV 0.005 
(0.053) 
0.920 
-0.003 
(0.064) 
0.968 
0.018 
(0.092) 
0.843 
0.030 
(0.112) 
0.787 
Number of common duplication CNVs  -0.003 
(0.042) 
0.945 
-0.006 
(0.053) 
0.913 
0.006 
(0.069) 
0.926 
0.011 
(0.087) 
0.896 
Burden of common duplication CNVs  -0.00003 
(0.0002) 
0.883 
-0.00002 
(0.0003) 
0.946 
-0.00003 
(0.0004) 
0.931 
-0.000009 
(0.0005) 
0.985 
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Table 3: NEWMEDS CNV results for CNVs annotated to encompass exonic regions of genes. Regression coefficient is standardized and can be interpreted as a measure of effect size.. 
Positive values of regression coefficient mean that carriers of more minor alleles had better treatment outcome. Negative values of regression coefficient mean that carriers of more minor alleles 
had worse outcomes. 
EXONIC CNVs Whole Sample Analysis 
(n=1,565) 
Serotonergic Analysis 
(n=1,046) 
Noradrenergic Analysis 
(n=519) 
Gene by Drug Interaction 
(n=1,565) 
Coefficient 
(SE) 
p-value Coefficient 
(SE) 
p-value Coefficient 
(SE) 
p-value Coefficient 
(SE) 
P-value 
Any CNV -0.028 
(0.051) 
0.591 
-0.038 
(0.062) 
0.546 
0.008 
(0.090) 
0.929 
0.054 
(0.109) 
0.623 
Number of CNVs  -0.002 
(0.025) 
0.943 
-0.014 
(0.031) 
0.656 
0.032 
(0.043) 
0.458 
0.053 
(0.053) 
0.322 
Burden of CNVs  0.00003 
(0.00005) 
0.547 
0.00001 
(0.00008) 
0.855 
0.00005 
(0.00007) 
0.466 
0.00005 
(0.0001) 
0.644 
Any deletion CNV -0.064 
(0.061) 
0.300 
-0.070 
(0.075) 
0.346 
-0.036 
(0.108) 
0.737 
0.057 
(0.131) 
0.661 
Number of deletion CNVs  -0.073 
(0.051) 
0.148 
-0.067 
(0.063) 
0.285 
-0.075 
(0.086) 
0.387 
0.012 
(0.107) 
0.911 
Burden of deletion CNVs  0.000008 
(0.00007) 
0.916 
-0.0001 
(0.0002) 
0.404 
0.00004 
(0.00008) 
0.589 
0.0002 
(0.0002) 
0.274 
Any duplication CNV 0.019 
(0.050) 
0.701 
-0.008 
(0.061) 
0.893 
0.091 
(0.087) 
0.298 
0.102 
(0.106) 
0.339 
Number of duplication CNVs  0.021 
(0.029) 
0.460 
0.003 
(0.035) 
0.930 
0.067 
(0.050) 
0.178 
0.066 
(0.061) 
0.276 
Burden of duplication CNVs  0.00005 
(0.00007) 
0.457 
0.00006 
(0.00008) 
0.521 
0.00007 
(0.0001) 
0.608 
0.00002 
(0.0002) 
0.898 
Any rare CNV 0.025 
(0.052) 
0.630 
0.010 
(0.064) 
0.878 
0.068 
(0.090) 
0.446 
0.073 
(0.110) 
0.508 
Number of rare CNVs  0.018 
(0.035) 
0.611 
-0.004 
(0.044) 
0.918 
0.071 
(0.059) 
0.228 
0.089 
(0.073) 
0.222 
Burden of rare CNVs  0.00005 
(0.00005) 
0.385 
0.00004 
(0.00009) 
0.672 
0.00006 
(0.00007) 
0.401 
0.00004 
(0.0001) 
0.744 
Any rare deletion CNV -0.027 
(0.069) 
0.702 
-0.030 
(0.084) 
0.723 
-0.021 
(0.125) 
0.869 
0.037 
(0.150) 
0.806 
Number of rare deletion CNVs  -0.050 
(0.058) 
0.389 
-0.039 
(0.072) 
0.592 
-0.068 
(0.097) 
0.481 
-0.008 
(0.121) 
0.945 
Burden of rare deletion CNVs  0.00002 
(0.00007) 
0.780 
-0.00009 
(0.0002) 
0.603 
0.00004 
(0.00008) 
0.589 
0.0002 
(0.0002) 
0.442 
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Any rare duplication CNV 0.041 
(0.055) 
0.451 
-0.011 
(0.068) 
0.866 
0.163 
(0.094) 
0.082 
0.187 
(0.115) 
0.105 
Number of rare duplication CNVs  0.047 
(0.041) 
0.253 
0.013 
(0.051) 
0.801 
0.129 
(0.071) 
0.068 
0.124 
(0.087) 
0.154 
Burden of rare duplication CNVs  0.00007 
(0.00009) 
0.386 
0.00007 
(0.0001) 
0.464 
0.00008 
(0.0001) 
0.561 
0.00002 
(0.0002) 
0.897 
Any common CNV -0.026 
(0.050) 
0.601 
-0.041 
(0.062) 
0.502 
0.009 
(0.088) 
0.915 
0.062 
(0.107) 
0.563 
Number of common CNVs  -0.025 
(0.038) 
0.510 
-0.028 
(0.048) 
0.562 
-0.013 
(0.063) 
0.831 
0.014 
(0.079) 
0.859 
Burden of common CNVs  -0.0001 
(0.0002) 
0.476 
-0.0001 
(0.0002) 
0.582 
-0.00009 
(0.0003) 
0.750 
0.00003 
(0.0004) 
0.928 
Any common deletion CNV -0.139 
(0.103) 
0.177 
-0.149 
(0.128) 
0.244 
-0.083 
(0.173) 
0.631 
0.079 
(0.215) 
0.712 
Number of common deletion CNVs  -0.135 
(0.100) 
0.175 
-0.143 
(0.122) 
0.242 
-0.083 
(0.173) 
0.631 
0.072 
(0.211) 
0.734 
Burden of common deletion CNVs  -0.0004 
(0.0004) 
0.365 
-0.0005 
(0.0005) 
0.326 
0.00003 
(0.0006) 
0.966 
0.0005 
(0.0008) 
0.500 
Any common duplication CNV 0.005 
(0.053) 
0.920 
-0.003 
(0.064) 
0.968 
0.018 
(0.092) 
0.842 
0.030 
(0.112) 
0.787 
Number of common duplication CNVs  -0.003 
(0.042) 
0.945 
-0.006 
(0.053) 
0.913 
0.006 
(0.069) 
0.926 
0.011 
(0.087) 
0.896 
Burden of common duplication CNVs  -0.00003 
(0.0002) 
0.883 
-0.00002 
(0.0003) 
0.946 
-0.00003 
(0.0004) 
0.931 
-0.000009 
(0.0005) 
0.985 
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